OncoMatch/Clinical Trials/NCT06455761
68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer
Is NCT06455761 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-DOTA-NI-FAPI04 and 68Ga-FAPI/18F-FDG for tumor.
Treatment: 68Ga-DOTA-NI-FAPI04 · 68Ga-FAPI/18F-FDG — As a novel radiotracer targeting fibroblast activation protein (FAP), 68Ga-DOTA-NI-FAPI04 is a novel agent incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a FAP-targeting. In this study, we observed the diagnostic performance of 68Ga-DOTA-NI-FAPI04 PET/CT in patients with different types of cancer, and compared its imaging results with those of 68Ga-FAPI or 18F-FDG PET/CT.
Check if I qualifyEligibility summary
For patients with Tumor.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify